AI Article Synopsis
- Primary burning mouth syndrome (BMS) is a chronic pain condition characterized by a burning sensation in the tongue and mouth, with no clear diagnostic criteria, leading to diagnosis through the exclusion of other causes.
- The exact cause of primary BMS remains uncertain, but it is often associated with neuropathic pain theories.
- The article discusses the diagnosis and treatment of primary BMS, highlighting a potential connection between the syndrome and malfunctioning pain modulation systems.
Article Abstract
Primary burning mouth syndrome (BMS) is a chronic pain of a burning quality affecting the tongue and intraoral mucosa. Currently, there are no definite diagnostic criteria; therefore, the diagnosis is made by exclusion of potential local and systemic causes that could justify the burning sensation. The etiology behind primary BMS remains unclear; however, the most acceptable theories link primary BMS with neuropathic pain. This article provides a review of primary BMS diagnosis, mechanisms, and treatment with focus on the association of BMS with pain modulation. Preliminary data are presented suggesting a link between primary BMS and a faulty inhibitory pain system.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3290/j.qi.a39403 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Natural potential difference induced functional optimization mechanism for Zn-based multimetal bone implants.
Bioact Mater
February 2025
Medical School of Chinese PLA, Beijing, 100039, China.
Zn-based biodegradable metals (BMs) are regarded as revolutionary biomaterials for bone implants. However, their clinical application is limited by insufficient mechanical properties, delayed degradation, and overdose-induced Zn toxicity. Herein, innovative multi-material additive manufacturing (MMAM) is deployed to construct a Zn/titanium (Ti) hetero-structured composite.
View Article and Find Full Text PDFEfficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC.
JTO Clin Res Rep
January 2025
Institut de Cancérologie de l'Ouest, 44805 Saint-Herblain, France.
Introduction: In a phase 1 study, bintrafusp alfa was found to have an encouraging clinical activity in patients with previously treated advanced NSCLC. This study evaluated the safety and efficacy of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC regardless of the programmed death-ligand 1 (PD-L1) expression status.
Methods: In this open-label, phase 1b/2 study (NCT03840915), eligible patients were assigned to one of four cohorts.
Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma.
Neurooncol Adv
December 2024
Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Background: This study is a phase II clinical trial to evaluate the efficacy, safety, and tolerability of the blood-brain barrier (BBB) permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma (HGG) (NCT01967810).
Methods: Seventy-three patients were enrolled in 3 separate arms-recurrent glioblastoma (GBM) (Arm 1), bevacizumab refractory GBM (Arm 2), and grade 3 anaplastic gliomas (AGs) (Arm 3). The study was started in October 2013, and the data were locked on September 29, 2017.
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.
Eur J Cancer
November 2024
University of Perugia, Unit of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy.
A unique collaboration of multi-disciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to two-centimeter safety margins. For a correct stage classification and treatment decision, a sentinel lymph node biopsy shall be offered in patients with tumor thickness ≥ 1.
View Article and Find Full Text PDFRetinal microvascular dysfunction in systemic sclerosis.
Microvasc Res
December 2024
Department of Cardiology, University Heart Center, University Hospital and University of Zurich, Zurich, Switzerland; Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address:
Background And Aims: Systemic sclerosis (SSc) is a systemic autoimmune disease, characterized by widespread microvasculopathy and fibrosis. Vascular and endothelial cell changes appear to precede other features of SSc. Retinal vascular analysis is a new, easy-to-use tool for the assessment of retinal microvascular function.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!